

AB SCIENCE S.A.

ISIN: FR0010557264 WKN: - Asset Class: **Stock**

Company



2022/07/01 17:35:21

Price
8.19 EUR

Difference ▲ 0.00%(0.00)



Contact Details

AB SCIENCE SA Tel: 33-1-47-20-00-14
 - - Fax: 33-1-47-20-24-11
 3, avenue George V Web: <http://www.ab-science.com>
 75008 Paris E-mail: contact@ab-science.com

Company Profile

AB Science SA operates as a pharmaceutical company. The firm specializes in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Its pipeline includes Masitinib and AB8939. The company was founded by Alain Moussy and Jean-Pierre Kinet on July 11, 2001 and is headquartered in Paris, France.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2021 | | 2020 | | 2019 | |
|---------------------------------------|------------|------------------------|------------|------------------------|------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 18,187,000 | | 26,325,000 | | 14,084,000 | |
| Common stock capital | | 469,000 | | 459,000 | | 435,000 |
| Fixed assets | 3,084,000 | | 3,363,000 | | 3,656,000 | |
| Equity capital of a company | | -23,198,000 | | -19,549,000 | | -26,829,000 |
| Cash and cash equivalents | 8,721,000 | | 20,660,000 | | 5,695,000 | |
| Accrued liabilities | | 1,084,000 | | 1,281,000 | | 817,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 17,482,000 | | 22,587,000 | | 19,527,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 15,528,000 | | 16,453,000 | | 14,845,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 6,721,000 | | 12,844,000 | | 12,344,000 |
| Total assets | 21,271,000 | 21,271,000 | 29,688,000 | 29,688,000 | 17,740,000 | 17,740,000 |

Balance notes

| | 2021 | 2020 | 2019 |
|----------------------------|----------|----------|----------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 98 | 92 | 103 |
| Equity ratio | -109.06% | -65.85% | -151.23% |
| Debt-equity ratio | -191.69% | -251.86% | -166.12% |

Others

| | 2021 | 2020 | 2019 |
|-------------------------|--------|--------|--------|
| Tax Expense Rate | 20.96% | 17.99% | 15.92% |

AB SCIENCE S.A.

ISIN: FR0010557264 WKN: - Asset Class: **Stock**

Income statement

| | 2021 | 2020 | 2019 |
|--|-------------|-------------|-------------|
| Turnover | 1,607,000 | 1,583,000 | 1,571,000 |
| Net income | -14,463,000 | -15,045,000 | -21,747,000 |
| EBIT | -18,242,000 | -18,188,000 | -25,848,000 |
| Operating income before taxes | -18,298,000 | -18,345,000 | -25,865,000 |
| Cash Flow | -17,204,000 | -13,461,000 | -15,227,000 |
| Net interest income | -56,000 | -157,000 | -17,000 |
| Research and development expenses | 15,104,000 | 16,149,000 | 19,705,000 |
| Income taxes | -3,835,000 | -3,300,000 | -4,118,000 |
| Result from investments in subsidiaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 16,398 | 17,207 | 15,252 |

Board of Directors

| | |
|-------------------------------|-----------------------------|
| Catherine Johnston-Roussillon | Member of Supervisory Board |
| Cécile de Guillebon | Member of Supervisory Board |
| Guillemette Latscha | Member of Supervisory Board |
| Patrick Moussy | Member of Supervisory Board |
| Renaud Sassi | Member of Supervisory Board |

Members of Management Board